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Available online 16 March 2017Background: Ethnic differences in clinical characteristics, stroke risk proﬁles and outcomes among atrial ﬁbrilla-
tion (AF) patientsmay exist. We therefore compared AF patients with previous stroke from Japan and the United
Kingdom (UK).
Methods:We compared clinical characteristics, stroke risk and outcomes among AF patients from the Fushimi AF
registrywho had experienced a previous stroke (Japan; n=688; 19.7%) and the Darlington AF registry (UK; n=
428; 19.0%).
Results: AF patients with previous stroke in Fushimi were signiﬁcantly younger (76.8 and 79.6 years of age in
Fushimi and Darlington; p b 0.01) with a lower proportion of females (37.4% vs. 45.1%; p = 0.01) than those
fromDarlington. Although the CHA2DS2-VASc scorewas lower in AF patients in Fushimi than those in Darlington
(5.18 vs. 5.57; p b 0.01), oral anticoagulation (OAC) was prescribed signiﬁcantly more frequently in Fushimi
(68.3%) than Darlington (61.7%) (p= 0.02). Multivariate logistic regression analysis showed that Japanese eth-
nicity was associatedwith a signiﬁcantly decreased risk of recurrent stroke (OR 0.59. 95% CI 0.36–0.97; p=0.04)
but a signiﬁcantly increased risk of all-cause mortality (OR 1.76, 95% CI 1.18–2.66; p b 0.01) in AF patients with
previous stroke.
Conclusions: AF patients with previous stroke in the UK were at higher risk of recurrent stroke compared to Jap-
anese patients, but OAC was utilised less frequently. There was a lower risk of recurrent stroke in the secondary
prevention cohort from the Fushimi registry, but an increased risk of all-cause mortality.
© 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Atrial ﬁbrillation
Previous stroke
Secondary prevention
Observational
Japan
United Kingdom1. Introduction
Atrial ﬁbrillation (AF) patients are at the increased risk of ischemic
stroke and death (Kopecky et al., 1987;Wolf et al., 1991). Of the various
risk factors, previous stroke or transient ischemic attach (TIA) are the
most powerful risk factors for subsequent ischemic stroke and confer
a signiﬁcant risk of mortality and recurrent stroke, approximately 12%
per year, if left untreated (Stroke Risk in Atrial Fibrillation Working
Group, 2007). Indeed, AF-related ischemic strokes are generally more
disabling and more often life-threatening than other types of stroke
(Marini et al., 2005). Thus, secondary prevention with oralm, Institute of Cardiovascular
.V. This is an open access article undanticoagulant (OAC) is crucial for AF patients with previous stroke
EAFT (European Atrial Fibrillation Trial) Study Group (1993). However,
little is known about possible differences in the clinical characteristics,
practices and outcomes between AF patients with previous stroke in
Japan compared to their British counterparts.
In this study, we used individual-level patient data from the Fushimi
AF registry and theDarlingtonAF registry to assess differences in clinical
characteristics, stroke risk proﬁles and outcomes among AF patients
with previous stroke or TIA.2. Materials and Methods
The details of the study designs, patient enrolment, deﬁnitions used,
and baseline patient clinical characteristics of the Fushimi AF registry
(UMIN Clinical Trials Registry: UMIN000005834) and the Darlingtoner the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics and medication of the secondary stroke prevention cohort at
baseline.
Number (%)
Fushimi AF registry
(Japan) (n= 688)
Darlington AF
registry (UK)
(n= 428) p value
Mean age (SD), years 76.8 (9.5) 79.6 (9.6) b0.001
Age b 65 years 70 (10.2) 28 (6.5) 0.002
Age 65–74 years 194 (28.2) 93 (21.7)
Age ≥ 75 years 424 (61.6) 307 (71.7)
Female gender 257 (37.4) 193 (45.1) 0.010
Heart failure 191 (27.8) 106 (24.8) 0.271
Hypertension 443 (64.4) 305 (71.3) 0.018
Diabetes mellitus 169 (24.6) 120 (28.0) 0.198
Vascular disease 85 (12.4) 97 (22.7) b0.001
Mean CHADS2 score (SD) 3.78 (0.97) 3.96 (0.94) 0.003
Mean CHA2DS2-VASc score
(SD)
5.18 (1.34) 5.57 (1.27) b0.001
Medication
OAC 470 (68.3) 264 (61.7) 0.023
Vitamin K antagonist 430 (62.5) 257 (60.1) 0.413
Non-vitamin K antagonist 40 (5.8) 7 (1.6) 0.001
Anti-platelet drugs 273 (39.7) 175 (40.9) 0.689
Concomitant use of OACs and
anti-platelet drugs
160 (23.3) 39 (9.1) b0.001
AF: atrial ﬁbrillation, OAC: oral anticoagulants; UK: United Kingdom.
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et al., 2015).
2.1. Fushimi AF Registry
The Fushimi AF registry is a prospective, observational registry
intended to identify the current status of AF patients in a community-
based clinical setting in Fushimi-ku, Kyoto, Japan (Akao et al., 2013).
Fushimi-ku is an urban administrative district in the southern area of
the city of Kyoto, with a total population of 284,000 (Japanese were
N99%) in 2011. The enrolment of patients with AF documented on a
12-lead electrocardiogram (ECG) or Holter monitoring at any time
(with no exclusion criteria) commenced in March 2011. Eighty institu-
tions (all members of Fushimi-Ishikai (Fushimi Medical Association))
participated in this registry and attempted to enroll all consecutive AF
patients under regular outpatient care or under admission. Follow-up
data was collected annually through review of the inpatient and outpa-
tient medical records, and contact with patients, relatives and/or refer-
ring physicians by mail or telephone. The study protocol was approved
by the ethical committees of the National Hospital Organization Kyoto
Medical Center and Ijinkai Takeda General Hospital.
2.2. Darlington AF Registry
The study population of the Darlington AF registry was derived from
all 105,000 patients who were registered at one of 11 general practices
serving the town of Darlington, UK (Shantsila et al., 2015), a market
town, with a resident population of 106,000 in 2011. According to the
last Census data in the Darlington cohort, N96% of population were
White Caucasian in Darlington. All patients with a history of AF or atrial
ﬂutter whose vital status in March 2013 was known, were eligible for
inclusion. Demographic and clinical data were collected from electronic
GP records (followup is still ongoing as part of routine clinical care in
this contemporary primary care population) including stroke risk fac-
tors and antithrombotic treatment (Cowan et al., 2013; Shantsila et al.,
2015).
In the present study, we used the data from all the AF patients in the
Fushimi AF registry (n=3499) and thosewith follow-up information in
theDarlingtonAF registry (n=2259).We identiﬁed those patientswho
had a history of stroke or TIA (n= 688 in Fushimi AF registry; n= 428
in Darlington AF registry) and categorized stroke risk using the CHADS2
(Gage et al., 2001) and CHA2DS2-VASc scores (Lip et al., 2010). OACwas
deﬁned as vitamin K antagonists (predominantly warfarin) and non-vi-
tamin K antagonists (dabigatran, rivaroxaban, apixaban and edoxaban).
The primary outcomes of the present study were the incidence of any-
cause recurrent stroke and all-causemortality during the 12-month fol-
low-up period. The secondary outcome was a composite of any-cause
stroke and all-cause mortality during the ﬁrst year.
2.3. Statistical Analysis
Continuous data are presented asmean and standard deviation (SD).
The incidence of stroke and all-cause mortality during the one-year fol-
low-up period were calculated as number and percentage. Censoring
was done for the ﬁrst event recorded. We compared categorical vari-
ables using the chi-square test and continuous variables using indepen-
dent samples t-test for normally distributed data or Mann-Whitney U
test for non-normal distribution. The unadjusted odds ratios were de-
termined using logistic regression for each risk proﬁle. The predictive
accuracy of CHADS2 and CHA2DS2-VASc scores for the study subjects
was determined using receiver-operator characteristic curves. Finally,
to determine independent risk factors for stroke and all-causemortality,
we carried outmultivariate logistic regression using age, sex, congestive
heart failure, hypertension, diabetes mellitus (DM), vascular disease
and OAC prescription at baseline as co-varieties. These analyses wereperformed using JMP version 12.2.0 (SAS Institute, Cary, NC). Statistical
signiﬁcance was set as a two-sided p-value of b0.05.
3. Results
The analyses included 1116 AF patients with history of stroke or TIA
at baseline (Fushimi AF registry, n = 688; Darlington AF registry, n =
428). The secondary prevention AF patients in the Fushimi registry
were signiﬁcantly younger, with fewer females and less likely to have
hypertension and vascular disease, comparedwith those in the Darling-
ton registry (Table 1).
Mean CHADS2 and CHA2DS2-VASc scores were signiﬁcantly lower in
Fushimi registry patients. The distribution of age group is shown in
Table 1. The proportion of elderly patients was higher in the Darlington
registry with N70% age ≥ 75 years; 17 (2.5%) patients in Fushimi and 18
(4.2%) patients in Darlington were aged ≥95 years. Patients with
CHADS2 score ≤ 3 were more frequent in Fushimi signiﬁcantly (p =
0.004) (Fig. 1A and B), while patients with a CHA2DS2-VASc score ≥ 6
were signiﬁcantly more common in the Darlington cohort (p b 0.001).
3.1. Antithrombotic Drug Use in Both Registries
OAC was prescribed more often in the Fushimi cohort than the Dar-
lington cohort (68.3% vs. 61.7%; p= 0.023) (Table 1). The prescription
of vitaminK antagonist (VKA, predominantlywarfarin)was comparable
(62.5% vs. 60.1%; p=0.413), but prescription of non-vitamin K oral an-
ticoagulants (NOAC) was signiﬁcantly higher in Japan than in the UK
(5.8% vs. 1.6%). The prescription of anti-platelet therapy drugs (APT), in-
cluding monotherapy or as combination therapy, was comparable
(39.7% vs. 40.9%; p = 0.689), with concomitant use of OAC and APT
being signiﬁcantly more frequent in the Fushimi cohort (23.3% vs.
9.1%), in all age groups and CHA2DS2-VASc scores. Fig. 2 shows the pre-
scription of antithrombotic therapy according to age (Fig. 2A) and
CHA2DS2-VASc score (Fig. 2B).
In Darlington, the age 85+ group had a higher rate of OAC and AP
use than all other age subgroups.
3.2. Study Outcomes
During one-year of follow-up, stroke occurred in 33 (4.8%) and 37
(8.6%) patients in the Fushimi and Darlington cohorts, respectively
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Table 2
Study outcomes during the ﬁrst year of follow-up for patients in the Fushimi and Darlin
Stroke
Fushimi AF
registry
Darlington AF
registry
Fushimi AF registry Darlington A
registry
Patients
[n (%)]
Patients
[n (%)]
Events
(n)
Incidece
rate (%)
Events
(n)
Inci
rateAll patients 688 (100.0) 428 (100.0) 33 4.8 37 8.6 0.53 0.33–0.87 93 13.5 42 9.8 1.44 0.98–2.13 116 16.9 73 17.1 0.99 0.72–1.36
Age 65–74 yr 194 (28.2) 93 (21.7) 6 3.1 7 7.5 0.39 0.12–1.21 14 7.2 4 4.3 1.73 0.60–6.24 18 9.3 10 10.7 0.85 0.38–1.99
Age ≥ 75 yr 424 (61.6) 307 (71.7) 25 5.9 28 9.1 0.62 0.35–1.09 73 17.2 37 12.1 1.52 1.00–2.34 92 21.7 60 19.5 1.14 0.79–1.65
Female 257 (37.4) 193 (45.1) 14 5.5 19 9.8 0.53 0.25–1.08 43 16.7 21 10.9 1.65 0.95–2.93 52 20.2 36 18.7 1.11 0.69–1.79
Heart failure 191 (27.8) 106 (24.8) 11 5.8 9 8.5 0.66 0.26–1.69 38 19.9 13 12.3 1.78 0.92–3.63 45 23.6 20 18.9 1.33 0.74–2.43
Hypertension 443 (64.4) 305 (71.3) 26 5.9 26 8.5 0.67 0.38–1.18 62 14.0 30 9.8 1.49 0.95–2.40 80 18.1 52 17.1 1.07 0.73–1.58
Diabetes
mellitus
169 (24.6) 120 (28.0) 8 4.7 14 11.7 0.38 0.15–0.91 25 14.8 17 14.2 1.05 0.54–2.08 30 17.8 28 23.3 0.71 0.40–1.27
Vascular
desease
85 (12.4) 97 (22.7) 7 8.2 8 8.3 1.00 0.34–2.90 16 18.8 14 14.4 1.37 0.63–3.05 20 22.5 19 19.6 1.26 0.62–2.58
Anti-platelet
therapy
273 (39.7) 175 (40.9) 14 5.1 19 10.9 0.44 0.21–0.91 39 14.3 19 10.9 1.37 0.77–2.50 48 17.6 37 21.1 0.80 0.49–1.29
OAC 470 (68.3) 264 (61.7) 19 4.0 24 9.1 0.42 0.22–0.78 46 9.8 14 5.3 1.94 1.07–3.72 60 12.8 36 13.6 0.93 0.60–1.56
AF: atrial ﬁbrillation, CI: conﬁdence interval, OAC: oral anticoagulant, OR: odds ratio. Signiﬁcant OR and 95% CI were presented in bold.
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202 H. Ogawa et al. / EBioMedicine 18 (2017) 199–203respectively; unadjusted OR 1.44 (95% CI) 0.98–2.13, p= 0.062) (Table
2). Japanese ethnicity was associated with a higher risk of all-cause
mortality in patients taking OAC (OR 1.94; 95% CI: 1.07–3.72) (Table 2).
Multivariate logistic regression analysis indicated that Japanese eth-
nicity was independently associated with an increased risk of all-cause
mortality (OR 1.76; 95% CI: 1.18–2.66) (Table 3).
Furthermore, heart failure was associated with an increased risk of
all-cause mortality (OR 1.61; 95% CI: 1.08–2.39) and OAC prescription
was associated with a reduced risk of death from any cause (OR 0.38;
95% CI: 0.26–0.56).
Analysis of the composite outcome of ‘stroke or all-cause mortality’
demonstrated that Japanese ethnicity was not associated with an inde-
pendent increased risk among AF patients with previous stroke (OR
1.15; 95% CI 0.82–1.61).
4. Discussion
Themajorﬁnding of the present studywas that the characteristics of
AF patients with previous stroke were different between the Fushimi
(Japan) and Darlington (UK) registries. AF patients in Fushimi were
younger, less likely to have various comorbidities and were at lower
risk of recurrent stroke. Second, OAC was prescribed only in approxi-
mately 60% of patients with previous stroke in both registries, despite
the indication for OAC given the high risk of recurrent stroke. Indeed,
prescription patterns of antithrombotic drugs were different between
the Fushimi and Darlington cohorts. OAC was prescribed more often
in the Fushimi cohort and the concomitant use of OAC and APT was
higher in Fushimi than Darlington. Third, ethnic setting (Fushimi vs.
Darlington) was an independent risk factor for outcomes; Fushimi reg-
istry subjects were signiﬁcantly associated with a decreased risk of
stroke and an increased risk of all-cause mortality.
4.1. Antithrombotic Drug Prescription in Fushimi (Japan) and Darlington
(UK)
AF patientswith a previous stroke are at high risk of recurrent stroke
and should be given anticoagulation therapy according to recent treat-
ment guidelines in both countries (Camm et al., 2010; JCS Joint
Working Group, 2014; National Institute for Clinical Excellence
(2014)), however, OAC was still under-utilised in both populations,
consistent with other data. (Go et al., 1999; Atarashi et al., 2011;
Cowan et al., 2013; Kakkar et al., 2013; Barra and Fynn, 2015) Despite
lower mean CHADS2 and CHA2DS2-VASc scores in Fushimi, overall pre-
scription of OAC was higher; the main difference in OAC prescription
was evident in greater NOAC prescriptions in Fushimi (although the
proportion was quite low in both countries). Indeed, the UK was one
of the European countries with previously relatively low NOAC pre-
scription. (Kirchhof et al., 2014).Table 3
Multivariate adjusted odds ratios for stroke and all-cause mortality in patients with previous s
Stroke All-cause m
OR 95% CI p value OR
Japanese ethnicity 0.59 0.36–0.97 0.039 1.76
Age b 65 Reference – – Reference
Age 65–74 0.99 0.34–3.62 0.992 0.77
Age ≥ 75 1.49 0.58–5.07 0.437 1.88
Female gender 1.24 0.75–2.07 0.399 1.20
Hypertension 1.31 0.76–2.35 0.335 0.99
Heart failure 1.04 0.59–1.77 0.890 1.61
Diabetes mellitus 1.31 0.75–2.21 0.339 1.34
Vascular disease 1.28 0.66–2.32 0.451 1.53
OAC prescription 0.92 0.56–1.55 0.754 0.38
CI: conﬁdence interval, OAC: oral anticoagulant, OR: odds ratio.In our study, the concomitant use of OAC and APT was higher in
Fushimi, although Japanese patients were less likely to have vascular
disease. The addition of APT to OAC in AF patients with atherosclerotic
cardiovascular disease is commonly observed in daily clinical practice.
However, combination of OAC and APT was associated with an in-
creased risk of major bleeding and with no reduction in stroke. (Flaker
et al., 2006; Toyoda et al., 2008).
4.2. Outcome Differences Between Fushimi (Japan) and Darlington (UK)
On multivariate logistic regression analysis, ethnic setting (Fushimi,
Japan) was associated with a decreased risk of stroke. It might be possi-
ble that control of VKA and prescription of NOAC affect difference in risk
of stroke between Fushimi (Japan) and Darlington (UK). Indeed, the
higher stroke recurrence in Darlington may relate to the lower use of
OAC and NOAC in this population. However, the incident rate of stroke
in Darlington (8.6%/year) was consistent previous studies from Europe.
(Stroke Risk in Atrial Fibrillation Working Group, 2007) In contrast,
Kodani et al. (2016) reported that the two-year incidence of thrombo-
embolism in Japanese AF patients with secondary prevention was 2.2%
in patients with warfarin and 8.7% without warfarin. In a recent Japa-
nese sub-analysis of NOAC trials, the incidence of stroke or systemic em-
bolism for both warfarin and NOAC groups in Japan were generally
lower than global rates (Hori et al., 2011, 2012; Ogawa et al., 2011;
Shimada et al., 2015), Meanwhile, it was reported from NOAC trials
that Asians have the same or possibly higher risk of thromboembolism,
comparing non-Asians.(Chiang et al., 2014).
Mortality in AF can be high in the secondary prevention setting, for
example, Marini et al. (2005) reported that the one-year mortality
rate was 49.5% in ﬁrst-ever ischemic stroke patients with AF. We
found that ethnic setting (Fushimi) in our study was associated with
an increased risk of all-cause mortality. Unfortunately, we have scarce
details concerning fatal stroke and cause of death in this cohort. Differ-
ences, in ethnicity, culture, lifestyle, religion, and the comprehensive
management of patients with previous stroke within different local
health care systems, all inﬂuence differences in all-cause mortality.
In the combined Fushimi and Darlington cohorts, OAC was indepen-
dently associated with lower all-cause mortality and ‘stroke +mortali-
ty’ – this is consistent with the historical trials where OAC signiﬁcantly
reduced mortality. In ‘real world’ registries such as this, some deaths
may be undiagnosed strokes, as no postmortems are mandated nor
events adjudicated (unlike a clinical trial).
4.3. Limitations
The study is limited by its analysis of combined data from two differ-
ent cohorts of AF patients in Japan andUK.Differences in themethods of
data collection among the two databases were evident, and the datatroke.
ortality Stroke + All-cause mortality
95% CI p value OR 95% CI p value
1.18–2.66 0.005 1.15 0.82–1.61 0.415
– – Reference – –
0.32–2.05 0.577 0.97 0.45–2.27 0.943
0.88–4.63 0.106 2.17 1.11–4.78 0.022
0.81–1.77 0.355 1.17 0.84–1.63 0.362
0.67–1.50 0.976 1.07 0.76–1.53 0.710
1.08–2.39 0.019 1.43 1.00–2.02 0.048
0.88–2.01 0.175 1.33 0.92–1.89 0.127
0.94–2.45 0.085 1.31 0.85–1.98 0.214
0.26–0.56 b0.001 0.51 0.37–0.70 b0.001
203H. Ogawa et al. / EBioMedicine 18 (2017) 199–203were not collected from clinical institutions all over their respective
country. Also, antithrombotic drugs and doses were selected at the dis-
cretion of the attending physician andwere not randomized. Indeed,we
cannot account for physician (or patient) preferences in management
decisions, although national guidelines in both UK and Japan do not
markedly differ in their approaches. We also have no data on the type
of previous stroke and neurological severity/disability of the patients,
such as National Institute of Health Stroke Scale (NIHSS) or modiﬁed
Rankin scale (mRS). Darlington is a small town in the UK, and there is
no indication that results from this town generalize to other UK white
populations from other small UK towns, rural areas and larger cities
given wide variation in healthcare across the UK. Unmeasured or resid-
ual confounders may remain, despite our multivariate analyses
adjusting for differences in demography and comorbidities.
5. Conclusions
AF patients with previous stroke in Darlington (UK) were at higher
risk of recurrent stroke compared to Fushimi (Japan) patients, but
OACwas less frequently used. Therewas a lower risk of recurrent stroke
in the secondary prevention cohort from the Fushimi registry, but an in-
creased risk of all-cause mortality.
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